Siemens Healthineers’ Innovance Antithrombin Assay Cleared by FDA as Companion Diagnostic for Sanofi’s Qfitlia

31 March 2025 | Monday | News


First and only assay approved to guide AT-based dosing of Qfitlia™ in hemophilia A or B patients, enabling personalized treatment through monitoring of antithrombin activity levels.

  • The assay now can measure antithrombin (AT) activity levels for people treated with Qfitlia
  • Measuring AT activity levels helps people receive the appropriate dose, initially and over time
  • The test is used before and during treatment with Qfitlia as part of the AT-based dosing regimen

Siemens Healthineers announced  its Innovance Antithrombin assay has achieved FDA clearance for a new claim allowing it to be used as a companion diagnostic test for people receiving treatment with Qfitlia (fitusiran), a Sanofi hemophilia therapy. Hemophilia is a lifelong genetic bleeding disorder that significantly affects the day-to-day lives of people living with the disease, creating potentially life-threatening risks from otherwise normal situations experienced by those without hemophilia. The body’s inability to clot blood effectively can prolong bleeding after injuries, result in excessive bruising and joint pain, and increase risks during surgery or other medical procedures.

"When we collaborate to innovate, we can achieve impactful advancements that can change lives and improve patient outcomes," said Bob Stowers, head of Specialty Lab Solutions, Diagnostics, Siemens Healthineers


Qfitila will support people living with hemophilia A or B, with or without inhibitors, by helping to rebalance one of the body’s critical clotting mechanisms to prevent bleeding. The Innovance Antithrombin blood test from Siemens Healthineers will aid in monitoring patients’ AT activity to support Qfitlia dosing in adult and pediatric patients aged 12 years and older. It is the only assay cleared for this indication.

“Every healthcare industry player has a meaningful role in driving patient care forward. When we collaborate to innovate, we can achieve impactful advancements that can change lives and improve patient outcomes. Diagnostics tests such as the Siemens Healthineers Innovance Antithrombin assay provide greater clinical utility when test results directly aid patients' next step in their treatment,” said Bob Stowers, head of Specialty Lab Solutions, Diagnostics, Siemens Healthineers.

The Innovance Antithrombin assay from Siemens Healthineers is used broadly to detect genetic or acquired AT deficiencies.

News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close